⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9307288 | 0.97 | DNM1 (0.44) | — | |
| SCHEMBL6614504 | 0.97 | DNM1 (0.44) | — | |
| SCHEMBL6682548 | 0.97 | DNM1 (0.44) | — | |
| SCHEMBL4615822 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL6023728 | 0.95 | DNM1 (0.42) | — | |
| SCHEMBL341549 | 0.91 | — | — | |
| SCHEMBL2519667 | 0.84 | — | — | |
| Butane SCHEMBL27839119 | 0.81 | DNM1 (0.38) | — | |
| Putrescine SCHEMBL27738865 | 0.81 | NFKB1 (0.54) | — | |
| SCHEMBL3027430 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228772-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2025-07-17 | — | — | US | claimed |
| EP-4536194-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | EsoCap AG (CH) | 2025-04-16 | — | — | EP | claimed |
| WO-2023237426-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2023-12-14 | — | — | WO | claimed |
| US-20190167632-A1 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | MUELLER WOLFGANG S (US) | 2019-06-06 | — | — | US | claimed |
| US-20190125779-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2019-05-02 | — | — | US | claimed |
| US-10238622-B2 | Methods of treating and preventing/reducing the likelihood of Mesial temporal lobe epilepsy (TLE) | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2019-03-26 | — | — | US | claimed |
| US-20170042929-A9 | Methods of Treating Neurological Diseases | UNIVERSITY OF HOUSTON | 2017-02-16 | — | — | US | claimed |
| WO-2016109624-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2016-07-07 | — | — | WO | claimed |
| US-20150051166-A1 | Methods of Treating Neurological Diseases | ZIBURKUS JOKUBAS (US) | 2015-02-19 | — | — | US | claimed |
| WO-2014028883-A1 | METHODS OF TREATING OF NEUROLOGICAL DISEASES | UNIVERSITY OF HOUSTON (US) | 2014-02-20 | — | — | WO | claimed |
| WO-2003026563-A9 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | UNIV RAMOT (IL) | 2004-04-22 | — | — | WO | claimed |
| EP-1344524-A1 | Reflux inhibitors | AstraZeneca AB (SE) | 2003-09-17 | — | — | EP | claimed |
| EP-0936906-B1 | REFLUX INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-10 | — | — | EP | claimed |
| US-20030162754-A1 | Use of GABA and GABAB agonists | TUFTS UNIVERSITY | 2003-08-28 | — | — | US | claimed |
| WO-2003026563-A2 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-04-03 | — | — | WO | claimed |
| WO-2002100871-A1 | NEW COMPOUNDS USEFUL IN REFLUX DISEASE | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-6117908-A | Use of GABAB receptor agonists as reflux inhibitors | ASTRA AKTIEBOLAG (SE) | 2000-09-12 | — | — | US | claimed |
| EP-0936906-A1 | REFLUX INHIBITORS | Astra Aktiebolag (SE) | 1999-08-25 | — | — | EP | claimed |
| WO-1998011885-A1 | REFLUX INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-03-26 | — | — | WO | claimed |
| WO-1996011680-A2 | USE OF GABA AGONISTS IN THE TREATMENT OF EMESIS | GLAXO GROUP LIMITED (GB) | 1996-04-25 | — | — | WO | claimed |